Effect of BM-MSCs on Chronic AMR After Kidney Transplantation
Efficacy and Safety of Bone Marrow-derived Mesenchymal Stem Cells (BM-MSCs) on Chronic Antibody-mediated Rejection (cAMR) After Kidney Transplantation: A Multi-center Perspective Study
Sponsor: First Affiliated Hospital, Sun Yat-Sen University
Listed as NCT02563340, this PHASE1/PHASE2 trial focuses on Kidney Transplantation and remains ongoing. Sponsored by First Affiliated Hospital, Sun Yat-Sen University, it has been updated 6 times since 2015, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
6 versions recorded-
Sep 2024 — Present [monthly]
Unknown PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE1/PHASE2
Status: Unknown Status → Unknown · Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Unknown Status PHASE1_PHASE2
-
Jun 2018 — Jan 2021 [monthly]
Unknown Status PHASE1_PHASE2
-
Feb 2018 — Jun 2018 [monthly]
Unknown Status PHASE1_PHASE2
Status: Not Yet Recruiting → Unknown Status
▶ Show 1 earlier version
-
Jan 2017 — Feb 2018 [monthly]
Not Yet Recruiting PHASE1_PHASE2
First recorded
Nov 2015
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- First Affiliated Hospital, Sun Yat-Sen University
- Second Affiliated Hospital of Guangzhou Medical University
For direct contact, visit the study record on ClinicalTrials.gov .